The Next Breakthrough in Schizophrenia Could be a Digital Therapeutic
A phase 3 trial has demonstrated that CT-155, a smartphone app, can reduce the negative symptoms of schizophrenia.
CT-155 integrates psychosocial interventions delivered using an adaptive goal-setting technique and was developed by Boehringer Ingelheim and Click Therapeutics.
According to data presented at the 38th Annual European College of Neuropsychopharmacology Congress, CT-155 is the first experimental prescription digital therapy to demonstrate good tolerability and exhibit no significant adverse events when administered with an antipsychotic treatment.
A prescription digital therapy has demonstrated that it can reduce the negative symptoms of schizophrenia.
- An estimated 24 million worldwide have schizophrenia, according to the World Health Organization.
- People with schizophrenia have persistent delusions and hallucinations.
Author's summary: Digital therapeutic CT-155 reduces schizophrenia symptoms.
More News
- The 5 Biggest State Tax Cuts for Millionaires this Year
- It's official - Pennsylvania, New Jersey and Delaware among states that must switch to daylight saving time - these are the ones that must not
- Texas faces heightened wildfire threat amid ongoing drought
- China, the United States, and a Critical Chokepoint on Minerals
- 4 weird driving myths that are actually dangerous, plus 1 that's just stupid
- How Creators Changed Nobody Wants This Season Two For Adam Brody and Leighton Meester
- Inside the Chicago Resistance
- Maintaining egg production during cold months - High Plains Journal
- Chelsea enjoy thumping win at Forest - West London Sport
- Adams, Ejuke Fail To Help Sevilla Close Gap On Madrid After Defeat To Mallorca